FeLV Study Underway

A new study on FeLV is being undertaken but Imulan BioTherapeutics LLC.

Imulan BioTherapeutics LLC of Prescott, Ariz., has begun a multi-site clinical trial to further assess the effect of lymphocyte T-cell immunomodulator (LTCI) in cats with feline leukemia virus.

The company recently commercialized LTCI as a conditionally licensed treatment aid for cats infected with FeLV and feline immunodeficiency virus and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia or thrombocytopenia.

“[LTCI] is a potent regulator of lymphocyte production and function and has been shown to increase lymphocyte numbers and interleukin-2 production in animals,” said Craig Woods, DVM, chief executive officer of Imulan. “Lymphocytes and interleukin-2 play a pivotal role in eliciting an immune response against viruses. Imulan believes this immunological approach will be far more effective than metabolic drug approaches, none of which are approved for feline viral infections.”


Leave a Comment


Your email address will not be published. Required fields are marked *



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.